ReviewIranian journal of basic medical sciences2015
Helicobacter pylori in Iran: A systematic review on the antibiotic resistance.
Review in Iranian journal of basic medical sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- The magnitude of antibiotic resistance to Helicobacter pylori in Africa and identified mutations which confer resistance to antibiotics: systematic review and meta-analysis.BMC infectious diseases · 2018Pooled it
- Meta-analysis: High-dose vs. low-dose metronidazole-containing therapies for Helicobacter pylori eradication treatment.PloS one · 2018Pooled it
- Comparison of the Efficacy of 12-day Concomitant Quadruple Therapy versus 14-day High dose Dual Therapy as a First-lineThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2024Trial
- Nigella sativa powder for helicobacter pylori infected patients: a randomized, double-blinded, placebo-controlled clinical trial.BMC complementary medicine and therapies · 2023Trial
- Comparison between daily single-dose triple therapy and conventional triple therapy on patient compliance and Helicobacter pylori eradication: A randomized controlled trial.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2018Trial
- Trial
- A comparative study of the effect of 10-day esomeprazole containing levofloxacin versus clarithromycin sequential regimens on the treatment of Iranian patients withIndian journal of pharmacologyTrial
- Association of IL-10 promoter and IL-12 gene polymorphisms with the risk of symptomatic Helicobacter pylori infection.BMC gastroenterology · 2026Article
- Antibiotic Resistance Identification Among the Patients withMiddle East journal of digestive diseases · 2025Article
- A review for non-antibiotic treatment ofFrontiers in microbiology · 2024Review
- Unveiling the Antibacterial Properties of Statins: AnAdvances in pharmacological and pharmaceutical sciences · 2024Article
- Helicobacter pylori strains isolated from raw poultry meat: frequency and molecular characteristics.Scientific reports · 2023Article
- Article
- Effects of 14-days bismuth- and tetracycline-containing quadruple therapy with concomitant regimen for the first lineCaspian journal of internal medicine · 2023Article
- A Survey ofAntimicrobial agents and chemotherapy · 2022Article
- Efficacy of 14-day concomitant quadruple therapy and 14-day high-dose dual therapy onGastroenterology and hepatology from bed to bench · 2022Article
- Article
- Antibiotic resistance pattern and frequency of cagA and vacA genes in Helicobacter pylori strains isolated from patients in Tabriz city, Iran.BMC research notes · 2021Article
- Persister cells as a possible cause of antibiotic therapy failure inJGH open : an open access journal of gastroenterology and hepatology · 2021Article
- Cost-effectiveness analysis of two routine therapeutic methods forGastroenterology and hepatology from bed to bench · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesHelicobacter pylori (H. pylori) is a pathogenic bacterium that colonizes the stomachs of approximately 50% of the world's population. Resistance of H. pylori to antibiotics is considered as the main reason for the failure to eradicate this bacterium. The aim of this study was to determine the rate of resistant H. pylori strains to various antimicrobial agents in different areas of Iran. MATERIALS AND
methodsA systematic review of literatures on H. pylori antibiotic resistance in Iran was performed within the time span of 1997 to 2013. Data obtained from various studies were tabulated as following, 1) year of research and number strains tested, 2) number of H. pylori positive patients, 3) study place, 4) resistance of H. pylori to various antibiotics as percentage, and 5) methods used for evaluation of antibiotic resistance.
resultsOver the period, a total of 21 studies on H. pylori antibiotic resistance have been conducted in different parts of Iran. In these studies, H. pylori resistance to various antibiotics, including metronidazole, clarithromycin, amoxicillin, tetracycline, ciprofloxacin, levofloxacin and furazolidone were 61.6%, 22.4%, 16.0%, 12.2%, 21.0%, 5.3% and 21.6%, respectively. We found no study on H. pylori resistance to rifabutin in Iran.
conclusionCompared to the global average, we noted that the prevalence of H. pylori resistance to metronidazole, clarithromycin, amoxicillin, and tetracycline has been rapidly growing in Iran. This study showed that in order to determine an appropriate drug regimen against H. pylori, information on antibiotic susceptibility of the bacterium within different geographical areas of Iran is required.
Indexed as
Identifiers
25810869PMC4366738W1928203757What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.